Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.

Abstract

Thirty-eight patients with cancer of the prostate were treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections--160 mg, 240 mg, and 320 mg--in this nonrandomized study. In contrast to studies with oral estrogens, there have been no cardiovascular complications at a mean follow-up of 12.9 +/- 0.7 months (SEM). Twenty-nine of the 38 patients (76%) have responded to therapy.

• Authors: P Henriksson, A Eriksson, R Stege, L Collste, A Pousette, B von Schoultz, K Carlström
• Journal: The Prostate (Prostate) Vol. 13 Issue 3 Pg. 257-61 ( 1988) ISSN: 0270-4137 [Print] United States
• PMID: 3211807 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Estradiol Congeners
• Estradiol
• polyestradiol phosphate

Topics

• Aged
• Cardiovascular Diseases (chemically induced, epidemiology)
• Estradiol (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Estradiol Congeners (adverse effects, therapeutic use)
• Follow-Up Studies
• Humans
• Injections, Intramuscular
• Male
• Prostatic Neoplasms (drug therapy)
• Risk Factors